Medtronic (MDT) Scheduled to Post Earnings on Tuesday

Medtronic (NYSE:MDT) will issue its quarterly earnings data before the market opens on Tuesday, November 19th. Analysts expect the company to announce earnings of $1.24 per share for the quarter. Medtronic has set its FY25 guidance at $5.42-5.50 EPS.Investors that are interested in participating in the company’s conference call can do so using this link.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, August 20th. The medical technology company reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03. The company had revenue of $7.97 billion during the quarter, compared to analysts’ expectations of $7.90 billion. Medtronic had a return on equity of 13.68% and a net margin of 12.06%. The firm’s revenue was up 3.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.20 EPS. On average, analysts expect Medtronic to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Medtronic Stock Up 1.8 %

Shares of MDT stock opened at $87.53 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.61 and a current ratio of 2.13. Medtronic has a fifty-two week low of $74.20 and a fifty-two week high of $92.68. The firm has a market capitalization of $112.25 billion, a PE ratio of 29.57, a P/E/G ratio of 2.51 and a beta of 0.84. The stock’s 50-day simple moving average is $89.48 and its 200-day simple moving average is $84.71.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on MDT. Citigroup raised their price target on shares of Medtronic from $85.00 to $92.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 1st. Stifel Nicolaus boosted their target price on shares of Medtronic from $85.00 to $87.00 and gave the company a “hold” rating in a research report on Wednesday, August 21st. Barclays increased their price target on Medtronic from $104.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, August 22nd. Oppenheimer boosted their price objective on Medtronic from $92.00 to $94.00 and gave the company a “market perform” rating in a report on Wednesday, August 21st. Finally, Truist Financial upped their target price on Medtronic from $90.00 to $93.00 and gave the stock a “hold” rating in a research note on Monday, October 14th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Medtronic has an average rating of “Hold” and an average price target of $95.80.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.